NUVL 📈 Nuvalent - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US6707031075

NUVL: Cancer, Therapies, Inhibitors, Lung Cancer, Brain Metastases, Tumors

Nuvalent, Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies for cancer patients. The company's lead product candidates are designed to address specific clinical challenges associated with existing treatments, such as emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases. For instance, NVL-520 is a novel ROS1-selective inhibitor that aims to overcome the limitations of current ROS1 tyrosine kinase inhibitors (TKIs) used to treat ROS1-positive non-small cell lung cancer (NSCLC). This candidate is currently in the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial, which is evaluating its safety and efficacy in patients with this specific type of cancer.

Another key product candidate in Nuvalent's pipeline is NVL-655, a brain-penetrant ALK-selective inhibitor. This therapy is being developed to address the clinical challenges associated with first-, second-, and third-generation ALK inhibitors, which can be limited by emergent treatment resistance, CNS-related adverse events, and brain metastases. The ALKOVE-1 Phase 1/2 clinical trial is currently ongoing, with the phase 2 portion assessing the safety and efficacy of NVL-655 in patients with ALK-positive cancer. Additionally, Nuvalent is working on NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor, which is designed to treat tumors driven by HER2ex20 and brain metastases, while minimizing treatment-limiting adverse events due to off-target inhibition of wild-type EGFR.

Nuvalent's approach to cancer therapy is centered on developing targeted treatments that can effectively penetrate the brain and address the complex challenges associated with cancer metastases. By focusing on specific molecular targets, such as ROS1, ALK, and HER2, the company aims to create therapies that can provide meaningful benefits to patients with limited treatment options. With its headquarters in Cambridge, Massachusetts, Nuvalent is well-positioned to leverage the region's rich biotechnology ecosystem and collaborate with leading research institutions to advance its pipeline of innovative cancer therapies.

As a publicly traded company listed on the NASDAQ stock exchange under the ticker symbol NUVL, Nuvalent is committed to transparency and accountability in its operations. The company's common stock is traded under the ISIN code US6707031075, and it is classified under the GICS Sub Industry: Biotechnology. For more information about Nuvalent and its pipeline of cancer therapies, investors and stakeholders can visit the company's website at https://www.nuvalent.com.

Additional Sources for NUVL Stock

NUVL Stock Overview

Market Cap in USD 5,740m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 2021-07-29

NUVL Stock Ratings

Growth 5y 77.7%
Fundamental -6.80%
Dividend -
Rel. Strength Industry 815
Analysts 4.5/5
Fair Price Momentum 81.38 USD
Fair Price DCF -

NUVL Dividends

No Dividends Paid

NUVL Growth Ratios

Growth Correlation 3m -73.9%
Growth Correlation 12m 55.6%
Growth Correlation 5y 89%
CAGR 5y 51.23%
CAGR/Mean DD 5y 1.91
Sharpe Ratio 12m 0.26
Alpha -32.87
Beta 1.63
Volatility 44.70%
Current Volume 342.2k
Average Volume 20d 533.7k
What is the price of NUVL stocks?
As of January 09, 2025, the stock is trading at USD 78.25 with a total of 342,160 shares traded.
Over the past week, the price has changed by -2.18%, over one month by -16.68%, over three months by -23.58% and over the past year by +7.49%.
Is Nuvalent a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Nuvalent is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -6.80 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NUVL as of January 2025 is 81.38. This means that NUVL is currently overvalued and has a potential downside of 4%.
Is NUVL a buy, sell or hold?
Nuvalent has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy NUVL.
  • Strong Buy: 8
  • Buy: 5
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0
What are the forecast for NUVL stock price target?
According to ValueRays Forecast Model, NUVL Nuvalent will be worth about 91.4 in January 2026. The stock is currently trading at 78.25. This means that the stock has a potential upside of +16.82%.
Issuer Forecast Upside
Wallstreet Target Price 115.1 47.1%
Analysts Target Price 115.1 47.1%
ValueRay Target Price 91.4 16.8%